Literature DB >> 25701930

Pathophysiology of major surgery and the role of enhanced recovery pathways and the anesthesiologist to improve outcomes.

Michael J Scott1, Timothy E Miller2.   

Abstract

Enhanced recovery pathways have been increasingly adopted into surgical specialties with the aim of reducing the stress response and improving the metabolic response to surgical insult. Enhanced recovery pathways encompass a large range of perioperative elements that together aim to restore a patient's gut function, mobility, function and well-being to preoperative levels as soon as feasible after major surgery. There is increasing evidence that rapid recovery and return to normal function reduces complications. This may not just have a benefit by reducing morbidity and mortality but also have an effect on long-term survival. There also may be additional benefits for patients with cancer.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anesthesia; Enhanced recovery pathway; Fast-track surgery; Metabolic response to surgery; Minimally invasive surgery; Pathophysiology of surgery; Perioperative care; Stress response to surgery

Mesh:

Year:  2015        PMID: 25701930     DOI: 10.1016/j.anclin.2014.11.006

Source DB:  PubMed          Journal:  Anesthesiol Clin        ISSN: 1932-2275


  3 in total

1.  Survival After Emergency General Surgery: What can We Learn from Enhanced Recovery Programmes?

Authors:  N Quiney; G Aggarwal; M Scott; M Dickinson
Journal:  World J Surg       Date:  2016-06       Impact factor: 3.352

2.  Organization of Multidisciplinary Cancer Care for the Surgical Patient: Role of Anesthesiologists.

Authors:  Elizabeth F Rieth; Gregory W Fischer; Anoushka M Afonso
Journal:  Curr Anesthesiol Rep       Date:  2018-10-08

3.  Risk factors for surgery-related muscle quantity and muscle quality loss and their impact on outcome.

Authors:  Laura van Wijk; Stijn van Duinhoven; Mike S L Liem; Donald E Bouman; Alain R Viddeleer; Joost M Klaase
Journal:  Eur J Med Res       Date:  2021-04-23       Impact factor: 2.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.